Company news
Pyxis Oncology, Inc. (NASDAQ:PYXS) news
Pyxis Oncology, Inc. news releases on 6ix. Latest, Oct 2, 2026: Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Press releases & updates
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
October 2, 2026
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
September 30, 2026
Pyxis Oncology Announces Proposed Public Offering
September 29, 2026
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 9, 2026
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 8, 2026
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
September 8, 2026
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
August 13, 2026
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
June 30, 2026
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
May 13, 2026
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
May 7, 2026
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
April 17, 2026
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 22, 2026
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
February 3, 2026
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
December 19, 2025
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
December 18, 2025
Pyxis Oncology to Participate in Upcoming Investor Conferences
November 3, 2025
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
November 3, 2025
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
October 13, 2025
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 9, 2025
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
October 1, 2025
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2025
Pyxis Oncology to Participate in September Investor and Industry Conferences
August 21, 2025
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
May 14, 2025
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
April 25, 2025
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 2, 2025
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
March 25, 2025
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
March 3, 2025
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
February 26, 2025
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
February 3, 2025
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
December 18, 2024
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
November 19, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
November 11, 2024
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
November 10, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
August 13, 2024
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
July 28, 2024
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 9, 2024
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 29, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 13, 2024
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 8, 2024
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
March 26, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
March 20, 2024
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
March 12, 2024
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
March 6, 2024
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
March 4, 2024
Pyxis Oncology Announces $50 Million Private Placement
February 26, 2024
Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer
November 27, 2023
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
November 6, 2023